Literature DB >> 11074444

N-methyl-D-aspartate receptor subunit NR2B is widely expressed throughout the rat diencephalon: an immunohistochemical study.

A M Khan1, B G Stanley, L Bozzetti, C Chin, C Stivers, M C Currás-Collazo.   

Abstract

Glutamate (Glu), a major excitatory neurotransmitter within the hypothalamus and thalamus, acts upon many receptors, including the N-methyl-D-aspartate (NMDA) subtype. Abundant evidence suggests that variations in the subunit composition of NMDA receptors (NMDA-Rs) contribute to differences in Glu's immediate electrophysiological effects as well as to the patterns of signal transduction cascades it triggers to mediate long-term changes in neuronal function. We have previously shown that hypothalamic NMDA-Rs containing the NR2B subunit may be involved in the control of eating as well as in the mediation of physiological responses to osmotic stimuli. To broaden our understanding of diencephalic NMDA-R participation in other functions, we localized the NR2B subunit in the diencephalon of the adult male rat using immunoperoxidase, immunogold, and immunofluorescence techniques and an affinity-purified polyclonal antibody specific for the NR2B subunit of the NMDA-R. In addition, we used a monoclonal NR2B antibody with immunoperoxidase detection to confirm the NR2B distribution seen with the polyclonal antibody. In the hypothalamus, the highest levels of NR2B immunoreactivity (-ir) were found in the magnocellular neurosecretory system, including the paraventricular and supraoptic nuclei. A new finding was that intense NR2B-ir was present within perivascular "accessory" magnocellular groups of this system, including the nucleus circularis, anterior fornical nucleus, and scattered clusters of lateral hypothalamic cells apposed to blood vessels. Robust NR2B-ir was also present within the arcuate nucleus, the median eminence, and the tuberal nucleus, and light immunostaining was found in all other hypothalamic nuclei examined. In the thalamus, the highest NR2B-ir was observed in the medial habenula and the anterodorsal, paraventricular, rhomboid, reticular, and dorsal lateral geniculate nuclei. As in the hypothalamus, all thalamic nuclei examined displayed at least light immunostaining for this subunit. Control sections, including those incubated with the polyclonal NR2B antibody preadsorbed with its fusion protein, were virtually devoid of immunostaining. This demonstration that the NR2B subunit of the NMDA-R is widely distributed in the diencephalon, implicates it in a wide variety of functions, and provides a useful anatomical framework for establishing a comprehensive map of Glu receptor populations within this major subdivision of the brain. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074444

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  10 in total

1.  Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning.

Authors:  S M Rodrigues; G E Schafe; J E LeDoux
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Backward shift of head direction tuning curves of the anterior thalamus: comparison with CA1 place fields.

Authors:  Xintian Yu; D Yoganarasimha; James J Knierim
Journal:  Neuron       Date:  2006-11-22       Impact factor: 17.173

3.  Distribution of NMDA and AMPA receptor subunits at thalamo-amygdaloid dendritic spines.

Authors:  Jason J Radley; Claudia R Farb; Yong He; William G M Janssen; Sarina M Rodrigues; Luke R Johnson; Patrick R Hof; Joseph E LeDoux; John H Morrison
Journal:  Brain Res       Date:  2007-01-17       Impact factor: 3.252

4.  Brainstem origins of glutamatergic innervation of the rat hypothalamic paraventricular nucleus.

Authors:  Dana R Ziegler; Monica R Edwards; Yvonne M Ulrich-Lai; James P Herman; William E Cullinan
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

5.  Enhanced NMDA receptor NR1 phosphorylation and neuronal activity in the arcuate nucleus of hypothalamus following peripheral inflammation.

Authors:  Jian-ming Peng; Long-sheng Xu; Qi Zhu; Shan Gong; Xian-min Yu; Shi-yu Guo; Gen-cheng Wu; Jin Tao; Xing-hong Jiang
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

6.  Perinatal exposure to organohalogen pollutants decreases vasopressin content and its mRNA expression in magnocellular neuroendocrine cells activated by osmotic stress in adult rats.

Authors:  Samuel Mucio-Ramírez; Eduardo Sánchez-Islas; Edith Sánchez-Jaramillo; Margarita Currás-Collazo; Victor R Juárez-González; Mhar Y Álvarez-González; L E Orser; Borin Hou; Francisco Pellicer; Prasada Rao S Kodavanti; Martha León-Olea
Journal:  Toxicol Appl Pharmacol       Date:  2017-06-01       Impact factor: 4.219

7.  Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists.

Authors:  Jitendra R Dave; Anthony J Williams; John R Moffett; Michael L Koenig; Frank C Tortella
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Rislenemdaz treatment in the lateral habenula improves despair-like behavior in mice.

Authors:  Ting Lei; Dan Dong; Meiying Song; Yanfei Sun; Xiaofeng Liu; Hua Zhao
Journal:  Neuropsychopharmacology       Date:  2020-03-08       Impact factor: 7.853

9.  The role of GluN2A and GluN2B NMDA receptor subunits in AgRP and POMC neurons on body weight and glucose homeostasis.

Authors:  Aykut Üner; Gabriel H M Gonçalves; Wenjing Li; Matheus Porceban; Nicole Caron; Milena Schönke; Eric Delpire; Kenji Sakimura; Christian Bjørbæk
Journal:  Mol Metab       Date:  2015-07-06       Impact factor: 7.422

10.  Computer Vision Evidence Supporting Craniometric Alignment of Rat Brain Atlases to Streamline Expert-Guided, First-Order Migration of Hypothalamic Spatial Datasets Related to Behavioral Control.

Authors:  Arshad M Khan; Jose G Perez; Claire E Wells; Olac Fuentes
Journal:  Front Syst Neurosci       Date:  2018-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.